An Exploratory Clinical Study to Evaluating the Safety and Efficacy of Infusiing Anti-CD19-CAR-T Cells Injection (Anti-CD19-CAR-T Cells) in Patients With Relapsed/Refractory Autoimmune Diseases

This is an investigator-initiated trial to evaluate the safety and efficacy of anti- CD19-CAR-T cells in the relapse or refractory autoimmune diseases.

开始日期2024-05-27

申办/合作机构

First Affiliated Hospital of Wenzhou Medical University

[+1]

100 项与 Anti-CD19 CAR-T Cells(SongGe Biotechnology) 相关的临床结果

登录后查看更多信息

100 项与 Anti-CD19 CAR-T Cells(SongGe Biotechnology) 相关的转化医学

登录后查看更多信息

100 项与 Anti-CD19 CAR-T Cells(SongGe Biotechnology) 相关的专利（医药）

登录后查看更多信息

项与 Anti-CD19 CAR-T Cells(SongGe Biotechnology) 相关的文献（医药）

2024-10-01·Cell Reports Medicine

Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome

Article

作者: Sayer-Klink, Anne ; Geis, Christian ; Heger, Lukas ; Borie, Dominic ; Wickel, Jonathan ; Schnetzke, Ulf ; Rinke, Jenny ; Hochhaus, Andreas ; Dudziak, Diana

Lambert-Eaton myasthenic syndrome (LEMS) is an autoantibody-mediated disease of the neuromuscular junction characterized by muscular weakness. Autoantibodies to presynaptic P/Q-type voltage-gated calcium channels (VGCCs) induce defective neuromuscular function. In severe cases, current immunosuppressive and immunomodulatory treatment strategies are often insufficient. First reports show beneficial effects of anti-CD19 chimeric antigen receptor (CAR)-T cell therapy in patients with autoantibody-mediated myasthenia gravis. We report a patient with isolated idiopathic LEMS treated with autologous anti-CD19-CAR-T cells. In this patient, CAR-T infusion leads to expansion of predominantly CD4⁺ CAR-T cells with a terminally differentiated effector memory cells re-expressing CD45RA (TEMRA)-like phenotype indicating cytotoxic capabilities and subsequent B cell depletion. VGCC antibody titers decrease, resulting in a clinical improvement of LEMS symptoms, e.g., 8-fold increase in walking distance. The patient does not show relevant side effects except for cytokine release syndrome grade 2 and intermittent neutropenia suggesting that anti-CD19 CAR-T cell therapy may be a treatment option in patients with LEMS.

100 项与 Anti-CD19 CAR-T Cells(SongGe Biotechnology) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
抗中性粒细胞胞质抗体相关性血管炎	临床1期	中国	Shanghai First Song Therapeutics Co., Ltd	2024-05-27
抗磷脂综合征	临床1期	中国	Shanghai First Song Therapeutics Co., Ltd	2024-05-27
肌炎	临床1期	中国	Shanghai First Song Therapeutics Co., Ltd	2024-05-27
系统性硬皮病	临床1期	中国	Shanghai First Song Therapeutics Co., Ltd	2024-05-27
干燥综合征	临床1期	中国	Shanghai First Song Therapeutics Co., Ltd	2024-05-27
系统性红斑狼疮	临床1期	中国	Shanghai First Song Therapeutics Co., Ltd	2024-05-27